Table 3.
Interaction analysis of the studied polymorphisms of TMPRSS2 on COVID-19 risk
| rs17854725 A > G | rs75603675 C > A | rs12329760 C > T | rs4303795 A > G | COVID-19 N (%) |
Control N (%) |
OR (95%CI) | P-value | |
|---|---|---|---|---|---|---|---|---|
| AG | AC | CT | AG | 19 (6.6) | 25 (8.7) | 1 [Reference] | ||
| AA | AC | CC | AA | 2 (0.7) | 10 (3.5) | 0.26 (0.05–1.35) | 0.093 | |
| AA | AC | CT | AA | 7 (2.4) | 7 (2.4) | 1.32 (0.39–4.39) | 0.655 | |
| AA | AC | CT | AG | 6 (2.1) | 13 (4.5) | 0.61 (0.19–1.89) | 0.388 | |
| AA | AC | CT | GG | 5 (1.7) | 8 (2.8) | 0.82 (0.23–2.92) | 0.762 | |
| AG | AA | CT | AG | 5 (1.7) | 7 (2.4) | 0.94 (0.26–3.43) | 0.925 | |
| AG | AC | CC | AG | 12 (4.2) | 6 (2.1) | 2.63 (0.84–8.29) | 0.093 | |
| AG | AC | CT | AA | 12 (4.2) | 10 (3.5) | 1.58 (0.56–4.42) | 0.383 | |
| AG | AC | CT | GG | 8 (2.8) | 7 (2.4) | 1.50 (0.46–4.88) | 0.496 | |
| AG | AC | TT | AA | 9 (3.1) | 4 (1.4) | 2.96 (0.79–11.09) | 0.099 | |
| AG | AC | TT | AG | 17 (5.9) | 4 (1.4) | 5.59 (1.61–19.36) | < 0.004* | |
| AG | CC | CC | AG | 8 (2.8) | 5 (1.7) | 2.10 (0.59–7.47) | 0.244 | |
| AG | CC | CT | AA | 8 (2.8) | 8 (2.8) | 1.32 (0.42–4.14) | 0.639 | |
| AG | CC | CT | AG | 12 (4.2) | 9 (3.1) | 1.75 (0.61–5.01) | 0.292 | |
| AG | CC | CT | GG | 8 (2.8) | 8 (2.8) | 1.32 (0.42–4.14) | 0.639 | |
| AG | CC | TT | AG | 10 (3.5) | 8 (2.8) | 1.65 (0.55–4.960 | 0.375 | |
| GG | AC | CT | AG | 8 (2.8) | 8 (2.8) | 1.32 (0.42–4.14) | 0.639 | |
| GG | CC | CT | AG | 9 (3.1) | 5 (1.7) | 2.37 (0.68–8.23) | 0.169 | |
OR, odds ratio; CI, confidence interval; COVID-19, coronavirus 2019. Genotypes with frequency < 2% were dropped. *P < 0.05 was considered statistically significant
Bold entities in all tables represent a p-value < 0.05